Date: 2017-03-28
Type of information: Licensing agreement
Compound: SEL24
Company: Selvita (Poland) Menarini (Italy)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: kinase inhibitor/PIM kinase inhibitor/FLT3 kinase inhibitor. SEL24 is a novel, orally-available small molecule, the first potent, dual inhibitor of PIM and FLT3 kinases. PIM and FLT3 protein kinases are over-expressed in multiple hematological cancers and certain solid tumors. SEL24 demonstrates strong cytotoxic effects in AML cell lines, independently of the FLT3 mutation status, in contrast to available target-selective kinase inhibitors. In preclinical studies, SEL24 has shown significant anticancer effects in multiple hematological xenograft models as a single agent, and has demonstrated synergistic effects with marketed standard of care compounds as well as therapies in advanced clinical development, such as cytarabine, without an associated increase in systemic toxicity.
Disease:
Details: • On March 28, 2017, Selvita and Berlin-Chemie Menarini, a company of the Menarini Group, announced that both companies have entered into a global license agreement for SEL24, a dual PIM/FLT3 inhibitor currently in Phase I/II trials in acute myeloid leukemia patients. The program entered Phase I/II in early 2017. According to the agreement, Selvita will grant Menarini Group an exclusive license to further research, develop, manufacture and commercialize SEL24 worldwide.
Financial terms: Under the terms of the agreement, Selvita will receive an upfront payment, and will be eligible to receive milestone payments and royalty on future sales.
Latest news:
